Patents by Inventor Kate Day

Kate Day has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR TREATING A DISEASE CHARACTERIZED BY INCREASED APPETITE
    Publication number: 20140161795
    Abstract: Insl5 has been found to be orexigenic, i.e. it increases appetite. Insl5, or a derivative or fragment thereof that retains the ability to bind to the GPR100 receptor, or an Insl5 antibody, are useful in therapy, in particular to treat anorexia nervosa, bulimia, cachexia or wasting disease.
    Type: Application
    Filed: July 24, 2013
    Publication date: June 12, 2014
    Inventors: JOHANNES GROSSE, HELEN HEFFRON, KATE DAY
  • Method for treating a disease characterized by reduced appetite
    Patent number: 8642539
    Abstract: Insl5 has been found to be orexigenic, i.e. it increases appetite. Insl5, or a derivative or fragment thereof that retains the ability to bind to the GPR100 receptor, or an Insl5 antibody, are useful in therapy, in particular to treat anorexia nervosa, bulimia, cachexia or wasting disease.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: February 4, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Johannes Grosse, Helen Heffron, Kate Day
  • COMPOUND FOR CONTROLLING APPETITE
    Publication number: 20100272727
    Abstract: Insl5 has been found to be orexigenic, i.e. it increases appetite. Insl5, or a derivative or fragment thereof that retains the ability to bind to the GPR100 receptor, or an Insl5 antibody, are useful in therapy, in particular to treat anorexia nervosa, bulimia, cachexia or wasting disease.
    Type: Application
    Filed: September 5, 2008
    Publication date: October 28, 2010
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Johannes Grosse, Helen Heffron, Kate Day
  • GRP 146 Receptor
    Publication number: 20090036394
    Abstract: We disclose GPR146 G-protein coupled receptor (GPCR) polypeptides comprising the amino acid sequence shown in SEQ ID NO. 3 or SEQ ID NO: 5, and homologues, variants and derivatives thereof. Nucleic acids capable of encoding GPR146 polypeptide are also disclosed, in particular, those comprising the nucleic acid sequences shown in SEQ ID No. 1A, SEQ ID No.1 B, SEQ ID No.2 or SEQ ID NO: 4. The GPR146 receptor is useful in the diagnosis and therapy of dyslipidaemias.
    Type: Application
    Filed: October 10, 2006
    Publication date: February 5, 2009
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Johannes Grosse, Justin Powell, John Dixon, Rosemary Thresher, Kate Day